Altimmune (ALT) Operating Leases (2015 - 2026)

Altimmune (ALT) has reported Operating Leases for 7 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases fell 19.75% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (down 19.75% YoY), while the FY2025 annual figure was $1.1 million, down 18.33% from the prior year.
• Operating Leases slipped to $1.1 million in Q1 2026 per ALT's latest filing, from $1.1 million in the prior quarter.
• Across five years, Operating Leases topped out at $1.5 million in Q2 2024 and bottomed at $44000.0 in Q1 2024.
• Historically, Operating Leases has averaged $1.0 million across 5 years, with a median of $1.2 million in 2025.
• Annual changes were most pronounced in 2023 — Operating Leases sank 73.96% — and 2025, when it jumped 2950.0%.
• Altimmune's Operating Leases stood at $672000.0 in 2022, then sank by 73.96% to $175000.0 in 2023, then jumped by 701.14% to $1.4 million in 2024, then dropped by 18.33% to $1.1 million in 2025, then fell by 5.94% to $1.1 million in 2026.
• Business Quant data shows ALT's Operating Leases at $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $1.2 million in Q3 2025.